The Medicines Patent Pool (MPP) announced that it has signed agreements with 35 companies to manufacture the generic version of Pfizer’s oral COVID-19 treatment nirmatrelvir,
The Medicines Patent Pool (MPP) announced that it has signed agreements with 35 companies to manufacture the generic version of Pfizer’s oral COVID-19 treatment nirmatrelvir,